1.70
price up icon1.19%   0.02
pre-market  Vorhandelsmarkt:  1.75   0.05   +2.94%
loading
Schlusskurs vom Vortag:
$1.68
Offen:
$1.72
24-Stunden-Volumen:
361.45K
Relative Volume:
0.40
Marktkapitalisierung:
$184.08M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-3.2692
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
+5.59%
1M Leistung:
+4.29%
6M Leistung:
-32.27%
1J Leistung:
+25.93%
1-Tages-Spanne:
Value
$1.665
$1.72
1-Wochen-Bereich:
Value
$1.61
$1.78
52-Wochen-Spanne:
Value
$1.05
$5.17

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name
Firmenname
Aclaris Therapeutics Inc
Name
Telefon
484-324-7933
Name
Adresse
701 LEE ROAD, WAYNE, PA
Name
Mitarbeiter
64
Name
Twitter
@aclaristx
Name
Nächster Verdiensttermin
2025-02-24
Name
Neueste SEC-Einreichungen
Name
ACRS's Discussions on Twitter

Vergleichen Sie ACRS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ACRS
Aclaris Therapeutics Inc
1.70 181.91M 27.08M -37.00M -18.46M -0.52
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-10 Fortgesetzt Piper Sandler Overweight
2025-05-28 Eingeleitet Wedbush Outperform
2025-03-18 Fortgesetzt Cantor Fitzgerald Overweight
2024-12-23 Hochstufung H.C. Wainwright Neutral → Buy
2024-11-20 Hochstufung Cantor Fitzgerald Neutral → Overweight
2024-11-19 Hochstufung BTIG Research Neutral → Buy
2024-11-19 Hochstufung Jefferies Hold → Buy
2024-11-19 Hochstufung Leerink Partners Market Perform → Outperform
2024-11-18 Hochstufung Piper Sandler Neutral → Overweight
2024-01-22 Herabstufung H.C. Wainwright Buy → Neutral
2023-11-13 Herabstufung William Blair Outperform → Mkt Perform
2023-10-03 Eingeleitet Evercore ISI Outperform
2022-12-14 Eingeleitet Stifel Buy
2022-12-01 Eingeleitet Goldman Buy
2022-10-06 Eingeleitet BTIG Research Buy
2021-07-23 Fortgesetzt Jefferies Buy
2021-06-15 Eingeleitet Piper Sandler Overweight
2021-04-21 Eingeleitet H.C. Wainwright Buy
2019-10-22 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-09-06 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2019-06-27 Herabstufung SVB Leerink Outperform → Mkt Perform
2019-05-06 Eingeleitet SVB Leerink Outperform
2018-03-28 Fortgesetzt Leerink Partners Outperform
2018-02-09 Eingeleitet Guggenheim Buy
2017-06-16 Eingeleitet Cantor Fitzgerald Overweight
2016-11-29 Eingeleitet Leerink Partners Outperform
2016-09-30 Eingeleitet JMP Securities Mkt Outperform
2016-06-10 Eingeleitet Guggenheim Buy
2015-11-02 Eingeleitet Citigroup Buy
2015-11-02 Eingeleitet Jefferies Buy
Alle ansehen

Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten

pulisher
08:17 AM

Momentum divergence signals in Aclaris Therapeutics Inc. chartTrend Following Ideas with Volume Confirmation - Newser

08:17 AM
pulisher
06:27 AM

Market reaction to Aclaris Therapeutics Inc.’s recent newsFree Expert Verified Stock Trade Ideas - Newser

06:27 AM
pulisher
04:50 AM

Using R and stats models for Aclaris Therapeutics Inc. forecasting Free Smart Trend Trading with Weekly Signals - Newser

04:50 AM
pulisher
04:38 AM

What is the risk reward ratio of investing in Aclaris Therapeutics Inc. stockHigh-performance stocks for savvy investors - jammulinksnews.com

04:38 AM
pulisher
12:25 PM

What are Aclaris Therapeutics Inc. company’s key revenue driversMaximize returns with effective portfolio management - jammulinksnews.com

12:25 PM
pulisher
Jul 27, 2025

What are analysts’ price targets for Aclaris Therapeutics Inc. in the next 12 monthsHarness the power of proven investment plans - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are the latest earnings results for Aclaris Therapeutics Inc.Capitalize on emerging growth stocks - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Published on: 2025-07-28 01:01:49 - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How Resilient Is Aclaris Therapeutics Inc. Stock During Economic DownturnsLong Term Secure Gain Stocks - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

Published on: 2025-07-27 19:20:18 - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How Efficient Is Aclaris Therapeutics Inc. at Controlling Operating CostsInsider Level Guidance - Newser

Jul 27, 2025
pulisher
Jul 25, 2025

What drives Aclaris Therapeutics Inc. stock priceRapidly expanding wealth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Aclaris Therapeutics Inc. Stock Analysis and ForecastConsistently high returns - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What institutions are buying Aclaris Therapeutics Inc. stock nowPhenomenal returns - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Aclaris Therapeutics Inc. stockFree Predictions - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Why Aclaris Therapeutics Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser

Jul 25, 2025
pulisher
Jul 23, 2025

LENZ Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital appreciation - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is Aclaris Therapeutics Inc. a good long term investmentRapid capital growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

How Aclaris Therapeutics Inc. stock performs during market volatilityDaily Volume Leaders - Newser

Jul 22, 2025
pulisher
Jul 15, 2025

What makes Aclaris Therapeutics Inc. stock price move sharplyEntry Level Low Risk Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey

Jul 15, 2025
pulisher
Jul 12, 2025

Piper Sandler Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

Aclaris Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.50m - simplywall.st

Jul 11, 2025
pulisher
Jul 10, 2025

Plus Therapeutics (NASDAQ:PSTV) vs. Aclaris Therapeutics (NASDAQ:ACRS) Head-To-Head Survey - Defense World

Jul 10, 2025
pulisher
Jul 07, 2025

Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN

Jul 07, 2025
pulisher
Jul 07, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Jul 07, 2025

Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Aclaris Therapeutics Inc-Aktie (ACRS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Mehra Anand
Director
Nov 19 '24
Buy
2.25
666,666
1,499,998
710,030
Walker Neal
INTERIM PRESIDENT AND CEO
Aug 09 '24
Option Exercise
0.72
43,548
31,355
1,356,153
Leonard Braden Michael
10% Owner
Aug 05 '24
Buy
1.24
206,025
256,357
14,250,000
Leonard Braden Michael
10% Owner
Aug 02 '24
Buy
1.29
167,544
216,400
14,043,975
Leonard Braden Michael
10% Owner
Jul 30 '24
Buy
1.30
173,730
226,370
13,776,421
Leonard Braden Michael
10% Owner
Jul 31 '24
Buy
1.33
100,000
132,640
13,876,421
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):